A Real World Evidence of Lorlatinib for Taiwanese with advanced ALK Positive Non-Small Cell Lung Cancer

被引：0
|
作者：
Shih, J. -Y. [1 ]
Luo, Y. -H. [2 ]
Chang, G. -C. [3 ]
Chang, J. W. -C. [4 ]
Wang, C. -C. [5 ]
Yang, T. [6 ]
Fang, W. [7 ]
Shau, W. -Y. [7 ]
机构：
[1] Natl Taiwan Univ Hosp, Taipei, Taiwan
[2] Taipei Vet Gen Hosp, Taipei, Taiwan
[3] Chung Shang Med Univ Hosp, Taichung, Taiwan
[4] Chang Gung Memory Hosp Linko, Taoyuan, Taiwan
[5] Chang Gung Mem Hosp Kaohsiung, Kaohsiung, Taiwan
[6] Taichung Vet Gen Hosp, Taichung, Taiwan
[7] Pfizer, Taipei, Taiwan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
real world; lorlatinib; lung cancer;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.02-15
引用
收藏
页码：S475 / S475
页数：1
相关论文
共 50 条
  • [1] Real-world evidence of lorlatinib therapy in Taiwanese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer
    Shih, Jin-Yuan
    Luo, Yung-Hung
    Chang, Gee-Chen
    Chang, John Wen-Cheng
    Wang, Chin-Chou
    Yang, Tsung-Ying
    Fang, Wei-Tse
    Shau, Wen-Yi
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2024, 123 (08) : 875 - 881
  • [2] Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non-small cell lung cancer patients
    Lee, Po-Hsin
    Chen, Kun-Chieh
    Hsu, Kuo-Hsuan
    Huang, Yen-Hsiang
    Tseng, Jeng-Sen
    Yang, Tsung-Ying
    Chang, Gee-Chen
    ANTI-CANCER DRUGS, 2021, 32 (10) : 1099 - 1104
  • [3] Lorlatinib for the treatment of ALK-positive metastatic non-small cell lung cancer
    Choo, Joan Rou-En
    Soo, Ross A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (04) : 233 - 240
  • [4] Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?
    Mogenet, Alice
    Tomasini, Pascale
    Greillier, Laurent
    Barlesi, Fabrice
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S383 - S386
  • [5] Real-world Analysis of the Efficacy and Safety of lorlatinib in Patients with ALK-Positive Non-small Cell Lung Cancer in Korea
    不详
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S402 - S402
  • [6] Efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC) and ALK kinase domain mutations
    Shaw, Alice T.
    Martini, Jean-Francois
    Besse, Benjamin
    Bauer, Todd M.
    Lin, Chia-Chi
    Soo, Ross A.
    Riely, Gregory J.
    Ou, Sai-Hong Ignatius
    Clancy, Jill S.
    Li, Sherry
    Thurm, Holger
    Satouchi, Miyako
    Camidge, D. Ross
    Kao, Steven
    Chiari, Rita
    Gadgeel, Shirish
    Felip, Enriqueta
    Solomon, Benjamin J.
    CANCER RESEARCH, 2018, 78 (13)
  • [7] New drug approval: First-line lorlatinib in advanced ALK-positive non-small cell lung cancer
    Pasquier, Corentin
    Basse, Clemence
    BULLETIN DU CANCER, 2022, 109 (09) : 877 - 878
  • [8] Therapeutic strategies in advanced ALK positive non-small cell lung cancer
    Tiotiu, A.
    Billon, Y.
    Vaillant, P.
    Menard, O.
    Hofman, P.
    Mascaux, C.
    REVUE DES MALADIES RESPIRATOIRES, 2019, 36 (10) : 1107 - 1116
  • [9] First-line lorlatinib for advanced ALK-positive non-small-cell lung cancer
    Lin, Jessica J.
    Gainor, Justin F.
    LANCET RESPIRATORY MEDICINE, 2023, 11 (04): : 302 - 304
  • [10] REAL-WORLD MEDICAL UTILIZATION AND OUTCOMES ASSOCIATED WITH TREATMENTS FOR ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER
    Mudumba, R.
    Romley, J. A.
    Nieva, J. J.
    VALUE IN HEALTH, 2024, 27 (12) : S611 - S611
12345